fda glp-1 warning news november 2025 Societies take stand against off-brand GLP-1s over safety concerns Ozempic Lawsuits: Possible Compensation For

Utility of Glucagon-like-Peptide-1-Receptor Agonists in Mast Cell Activation Syndrome. The American Journal of the Medical Sciences , vol

A network meta-analysis of 22 randomized controlled trials found that lean mass loss comprises approximately 25% of total weight lost on GLP-1 receptor agonists

Read Ipsos latest PoV, where we explore these topics in more depth: Ipsos has tracked MASH treatment since 2017

Available from: Linda Gigliotti 1 , Hope Warshaw 2 , Alison Evert 3 , Colleen Dawkins 4 , Julie Schwartz 5 , Caroline Susie 6 , Robert Kushner 7 , Savitha Subramanian 8 , Deepa Handu 9 , Mary Rozga 10 Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care

Healthline, updated July 26, 2023